Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00KHD
|
|||
| Former ID |
DIB008847
|
|||
| Drug Name |
TAK-128
|
|||
| Synonyms |
Y-128
Click to Show/Hide
|
|||
| Indication | Diabetic neuropathy [ICD-11: 8C0Z; ICD-10: G63, G63.2] | Phase 2 | [1] | |
| Company |
Mitsubishi Pharma Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thromboxane A2 receptor (TBXA2R) | Target Info | Modulator | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Platelet activation | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| Thromboxane signalling through TP receptor | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| Signal amplification | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.